AOD-9604 peptide before and after: what the trials actually show

Last updated 2026-07-24

What does the human trial data on AOD-9604 actually show?

The short answer is: not much that would excite a drug regulator. AOD-9604 (a 15-amino-acid fragment of human growth hormone, covering the 176-191 region) went through a phase II development program aimed at obesity, and the fat-loss signal in humans did not hold up as a clean, dose-dependent effect that clearly beat placebo. A 2004 review in Current Opinion in Investigational Drugs describes AOD-9604 in the metabolic drug pipeline of that era, tracking it as an hGH-fragment candidate positioned for obesity and lipid metabolism, without reporting a decisive human efficacy outcome ^[1]. By 2006, a broader review of obesity drugs in clinical development still listed AOD-9604 among candidates in the pipeline, again without the kind of unambiguous, replicated weight-loss result that would move a compound toward approval ^[2]. That gap between mechanism and outcome is the central fact anyone researching this peptide needs to sit with before they read another "before and after" post online. Series of "Gateways to clinical trials" round-ups published in Methods and Findings in Experimental and Clinical Pharmacology in 2003 and 2005 tracked AOD-9604 alongside dozens of other compounds moving through early trial phases in that period ^[3][4][5]. These are trial-tracking digests, not efficacy papers, but they confirm the compound was actively in human testing during the mid-2000s and never emerged from that phase with a marketed obesity indication anywhere in the world.

Is there a real 'before and after' for AOD-9604, or is it mostly marketing?

Almost all of the dramatic before-and-after photo pairs you'll find online are user-submitted, unblinded, and impossible to verify against dose, diet, or training changes happening at the same time. That's the honest answer. None of the peer-reviewed literature in the research record here includes photographic outcome data or standardized body-composition endpoints reported as a positive, replicated finding. The clinical development record shows AOD-9604 in trial pipelines for obesity ^[1][2], but no approved product, no FDA monograph, and no published phase III result confirming meaningful fat loss over placebo. You can check the approval status yourself: AOD-9604 does not appear in Drugs@FDA, the FDA's own database of approved drug products ^[6]. So when you see a transformation photo captioned "12 weeks on AOD-9604," you're looking at an anecdote, not a controlled result. That doesn't mean the person didn't lose fat. It means you can't attribute that fat loss to the peptide specifically, because there's no comparison group and no verified dosing history behind the photo.

What is the fragment rationale, and does it hold up?

The idea behind AOD-9604 is genuinely clever on paper. Growth hormone drives fat metabolism partly through its 176-191 fragment while a separate part of the molecule drives growth and insulin-resistance effects. Strip out that fragment, the thinking goes, and you might keep the fat-metabolizing action without the side effects tied to full-length hGH (joint swelling, insulin resistance, acromegaly-like changes). That's a reasonable hypothesis, and it's why AOD-9604 got real pharmaceutical investment and made it into human trials at all. But a plausible mechanism is not the same as a demonstrated clinical effect. The trial-tracking literature confirms the compound moved through development ^[3][4][5], and the metabolic-focused review from 2004 covers it as a candidate of interest ^[1], yet nothing in the published record shows the fragment produced a fat-loss effect in humans large enough and consistent enough to clear a regulatory bar. Reviews of the broader obesity drug landscape from the same period list it among many candidates that didn't reach market ^[2]. If you want the deeper mechanistic and dosing background, our main aod 9604 peptide overview covers the fragment biology and how it compares to full hGH in more detail.

How does AOD-9604 compare to options with stronger evidence?

This is the comparison that matters more than any before-and-after photo. Below is a rough evidence-strength comparison based on where each approach sits in the human trial and regulatory record.

The pattern here isn't subtle. Peptide and hormone-fragment candidates that reached approval for weight management went through phase III programs with large, replicated effect sizes. AOD-9604 stalled at the phase II stage for its obesity indication and never produced that kind of data. If your priority is the strongest available evidence for fat loss, that's the honest place to start, and it isn't AOD-9604.

Why do so many people report positive results anecdotally?

A few things are going on at once, and none of them require the peptide to be doing much of anything metabolically. First, most people running AOD-9604 protocols are also running a calorie deficit, resistance training, or both, because that's the standard advice paired with any peptide regimen. Second, placebo and expectation effects are real and well documented in weight-loss research generally; people who believe they're on an active compound often change behavior in ways that produce results independent of the compound itself. Third, survivorship bias in online testimonials is enormous. People who saw no change rarely post a before-and-after; people who did see change (often from the diet and training changes) post enthusiastically and credit the peptide. None of this proves AOD-9604 does nothing. It just means anecdotal photo evidence can't distinguish the peptide's effect from everything else happening in someone's routine, which is exactly why controlled trials exist and exactly why the trial record here matters more than testimonials.

Are there documented differences in AOD-9604 before and after results for women specifically?

There is no published human trial data broken out by sex showing a distinct AOD-9604 fat-loss response for women versus men. The trial-tracking literature from the 2003 to 2005 period doesn't report sex-stratified efficacy outcomes for this compound ^[3][4][5], and neither does the 2004 metabolic review ^[1] or the 2006 obesity pipeline review ^[2]. That means claims you may see framed as "AOD-9604 before and after female" results are, like the general before-and-after claims, anecdotal rather than trial-verified. Anyone telling you the peptide works differently or better for women is going beyond what the published record supports. If sex-based differences exist, they haven't been documented in the human obesity trial data that made it into the literature covered here.

Does AOD-9604 show up on drug tests, and does that affect athletes' use of it?

This is one area where the research record is genuinely solid, separate from the weak efficacy picture. A 2013 study in Drug Testing and Analysis found that AOD-9604 does not influence the WADA hGH isoform immunoassay, meaning it doesn't trigger a false positive or interfere with the standard test used to detect growth hormone doping ^[7]. That finding matters for a different reason than fat loss: it tells anti-doping labs the compound needs its own detection method rather than piggybacking on existing hGH tests. Broader reviews of analytical methods for detecting peptide drugs in doping controls, published in 2014 in the Journal of Pharmaceutical and Biomedical Analysis ^[8] and in Expert Review of Proteomics ^[9], describe the general challenge of catching small peptide drugs like AOD-9604 in sports testing. A 2016 method in the Journal of Separation Science specifically describes a direct urine injection, liquid chromatography, and ion mobility mass spectrometry approach built to screen for peptides under 2 kDa, the size class AOD-9604 falls into ^[10]. AOD-9604 is on WADA's prohibited list as a growth hormone releasing peptide/fragment; athletes should assume it is detectable by dedicated methods even though it doesn't cross-react with the standard hGH immunoassay.

What side effects or safety signals show up in the research on AOD-9604 and related peptides?

Recent 2026 reviews covering peptide therapies in orthopaedics and sports medicine include AOD-9604 among peptides used off-label for musculoskeletal and performance goals, and both flag the same core problem: safety and efficacy data for many of these compounds, including AOD-9604, remain limited compared to approved drugs. The orthopaedics review in JAAOS Global Research & Reviews covers therapeutic peptides broadly, including AOD-9604's classification and proposed use, without reporting a large safety database specific to it ^[11]. A companion 2026 review in Sports Medicine on approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance likewise treats AOD-9604 as an unapproved compound with a thin human safety record relative to FDA-approved options ^[12]. The practical takeaway: there isn't a large, published adverse-event database for AOD-9604 the way there is for approved obesity drugs. That cuts both ways. It means there's no strong signal of it being dangerous in the doses studied, but it also means nobody has done the large, long-term safety trials that would let you rule out uncommon risks with confidence. For a fuller rundown of reported side effects and what's actually documented versus anecdotal, see our aod 9604 peptide side effects page.

Why did AOD-9604 stall in clinical development instead of reaching approval?

The trial-tracking record shows AOD-9604 moving through phase I and phase II testing across the early-to-mid 2000s ^[3][4][5], with reviews from that same window covering it as an obesity-pipeline candidate ^[1][2]. What's absent from the public record is a phase III trial result strong enough to support a New Drug Application. Regulatory approval requires more than a plausible mechanism and an early-phase signal; it requires replicated, statistically convincing separation from placebo in adequately powered trials, and that data was not published for AOD-9604 in a form that moved it forward. Compare that to the FDA's own bulk drug substance framework: substances used in human compounding under 21 U.S.C. 353a are governed by lists set out in 21 CFR 216.23 (503A) ^[13]. AOD-9604 has been nominated for inclusion on FDA's list of bulk drug substances considered for compounding use, but nomination and inclusion are not the same as approval, and FDA's own nominated-substances list makes clear these are substances under review, not endorsed drugs ^[14][15]. You can verify current FDA-approved products yourself through Drugs@FDA ^[6]; AOD-9604 isn't there.

What should someone do with this information if they're considering AOD-9604 for fat loss?

Go in with clear eyes about what the trial record does and doesn't say. AOD-9604 has a coherent biological rationale, went through real human trials, and the weight-loss effect did not separate convincingly from placebo in the published development history ^[1][2]. That's not a reason to panic, but it is a reason not to expect it to outperform diet, training, or approved pharmacotherapy. If you're going to research further, start with dosing protocols and reconstitution steps documented from the trial literature rather than forum consensus. Our aod 9604 dosage guide and aod 9604 how to reconstitute page cover the practical mechanics, and the aod 9604 dosage calculator can help you work out concentrations if you're already committed to trying it. If you're sourcing it, look for a provider-reviewed route rather than an unverified reseller. AOD-9604 Co reviews providers and points readers toward the pharmacy partner that fulfills orders through that reviewed channel, rather than compounding or manufacturing anything itself; check our aod 9604 peptide for sale page before buying from anywhere else. The most honest recommendation, if the strength of human evidence is what matters to you, is to look at FDA-approved options with large phase III weight-management trial data behind them first, and treat AOD-9604 as a research-stage compound with an interesting story and a thin human efficacy record, not a proven fat-loss tool.

Frequently asked questions

Does AOD-9604 actually cause fat loss in humans?

The published trial record doesn't show a clear, replicated fat-loss effect over placebo. AOD-9604 went through phase II obesity trials, tracked in clinical trial digests from 2003 to 2005 ^[3][4][5], but no phase III result confirming meaningful weight loss beyond placebo has been published, and it is not FDA-approved for any indication ^[6].

Are AOD-9604 before and after photos reliable evidence?

No. These are unblinded, user-submitted photos with no verified dosing, diet, or training controls. They can't isolate the peptide's effect from concurrent calorie deficits or exercise changes, and no peer-reviewed source in the AOD-9604 literature reports photographic outcome data as a controlled finding.

Is there different evidence for AOD-9604 before and after female users versus male users?

No published trial data breaks out AOD-9604 fat-loss results by sex. The trial-tracking and review literature from 2003-2006 doesn't report sex-stratified efficacy ^{[1][2][3][4][5]}, so any claim about it working differently for women is anecdotal, not trial-verified.

Is AOD-9604 approved by the FDA?

No. AOD-9604 does not appear as an approved product in Drugs@FDA, the FDA's database of approved drug products ^[6]. It has been nominated for FDA's bulk drug substances list considered for compounding, but nomination is not approval ^[14][15].

Will AOD-9604 show up on a drug test?

A 2013 study in Drug Testing and Analysis found AOD-9604 does not interfere with the WADA hGH isoform immunoassay, so it won't trigger a false positive on that specific test ^[7]. It is on WADA's prohibited list, though, and dedicated small-peptide detection methods exist to catch it directly ^[8][9][10].

How does AOD-9604 compare to GLP-1 drugs like semaglutide for fat loss?

GLP-1 receptor agonists have large, replicated phase III trial data and FDA approval for weight management. AOD-9604 stalled at phase II for its obesity indication with no published result showing a clear separation from placebo ^[1][2]. If trial-strength evidence is your priority, GLP-1 drugs currently have far more of it.

What is the mechanism behind AOD-9604's fat-loss claim?

AOD-9604 is a 15-amino-acid fragment of the 176-191 region of human growth hormone, the region thought to drive fat metabolism without the growth-promoting or insulin-resistance effects of full-length hGH. It's a reasonable hypothesis, but the human trial record hasn't confirmed a strong clinical effect from it ^[1][2].

What side effects does AOD-9604 have?

There's no large published adverse-event database specific to AOD-9604. Recent 2026 reviews on peptide therapies in orthopaedics and sports medicine flag it as an unapproved compound with a thin human safety record compared to approved drugs ^[11][12]. See our side effects page for a full breakdown of what's documented versus anecdotal.

Why did AOD-9604 never make it to market as an obesity drug?

It progressed through phase I and II human trials in the 2000s ^[3][4][5] but the published record doesn't show a phase III result strong enough to support regulatory approval. A plausible mechanism and early-phase interest aren't the same as a demonstrated, replicated clinical benefit.

Can AOD-9604 be legally compounded by a pharmacy?

AOD-9604 has been nominated for FDA's list of bulk drug substances considered for use under 21 U.S.C. 353a compounding rules ^[13][14][15], but nomination alone doesn't confirm it meets the final criteria in 21 CFR 216.23 for 503A compounding. Check current FDA lists before assuming legal compounding status.

How long does it take to see AOD-9604 peptide results, if any?

There's no published trial timeline establishing a reliable window for fat-loss results, because the trials never confirmed a clear effect to time in the first place. Anecdotal reports vary widely (weeks to months), but without placebo-controlled data, no verified onset window exists.

Is AOD-9604 the same as HGH?

No. AOD-9604 is a small fragment (amino acids 176-191) of the full human growth hormone molecule, designed to isolate the fat-metabolizing region while leaving out the growth-promoting portion. It is structurally and functionally distinct from full-length recombinant hGH, which is FDA-approved for specific deficiency indications.

Sources

1. PubMed, Current Opinion in Investigational Drugs (2004): AOD-9604 was tracked as a metabolic/obesity drug candidate in the mid-2000s pipeline without a decisive human efficacy outcome reported.
2. PubMed, Current Opinion in Investigational Drugs (2006): A 2006 review of obesity drugs in clinical development listed AOD-9604 among candidates without a confirmed strong efficacy result.
3. PubMed, Methods and Findings in Experimental and Clinical Pharmacology (2003): AOD-9604 was tracked moving through early human trial phases in 2003 clinical trial digests.
4. PubMed, Methods and Findings in Experimental and Clinical Pharmacology (2003): A second 2003 trial-tracking digest also lists AOD-9604 among compounds in active human testing.
5. PubMed, Methods and Findings in Experimental and Clinical Pharmacology (2005): A 2005 trial digest confirms AOD-9604 remained in clinical trial tracking without reaching a marketed obesity indication.
6. FDA, Drugs@FDA database: AOD-9604 does not appear as an approved drug product in the FDA's Drugs@FDA database.
7. PubMed, Drug Testing and Analysis (2013): AOD-9604 does not influence or trigger the WADA hGH isoform immunoassay used in doping control.
8. PubMed, Journal of Pharmaceutical and Biomedical Analysis (2014): Analytical methods for detecting emerging peptide therapeutics like AOD-9604 in doping controls are a distinct technical challenge from standard hGH testing.
9. PubMed, Expert Review of Proteomics (2014): Detection of peptide drug candidates and analogs such as AOD-9604 in sports doping requires dedicated proteomic methods.
10. PubMed, Journal of Separation Science (2016): A direct urine injection LC-ion mobility mass spectrometry method was developed to screen for small peptides under 2 kDa, the size class including AOD-9604.
11. PubMed, JAAOS Global Research & Reviews (2026): A 2026 review of therapeutic peptides in orthopaedics covers AOD-9604's classification and use without reporting a large human safety database.
12. PubMed, Sports Medicine (2026): A 2026 review of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance treats AOD-9604 as an unapproved compound with limited human safety data.
13. Cornell Law, 21 U.S.C. 353a: Federal law governing pharmacy compounding of human drugs, including which bulk substances may be used.
14. eCFR, 21 CFR 216.23 (503A Bulks List): Defines the final list of bulk drug substances that may be used in 503A compounding.
15. FDA, bulk drug substances nominated for use in compounding: AOD-9604 appears on FDA's list of substances nominated for compounding consideration, which is distinct from approval.